2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7075
    Inulin 9005-80-5
    Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
    Inulin
  • HY-107469
    Pyridoxal 66-72-8 99.89%
    Pyridoxal is a neuroprotectant. Pyridoxal is one of the main forms of vitamin B6. Pyridoxal is phosphorylated by pyridoxal kinase to pyridoxal phosphate (HY-B1744). Pyridoxal is oxidized by the liver to 4-pyridoxic acid (HY-113493) and excreted in the urine. Pyridoxal has shown promise in the study of carpal tunnel syndrome (CTS).
    Pyridoxal
  • HY-108915
    Trimethylamine N-oxide dihydrate 62637-93-8 ≥98.0%
    Trimethylamine N-oxide dihydrate is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide dihydrate induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide dihydrate also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway.
    Trimethylamine N-oxide dihydrate
  • HY-113004
    3-Hydroxyvaleric acid 10237-77-1 ≥98.0%
    3-Hydroxyvaleric acid is a five-carbon ketone body byproduct that can undergo an anaplerotic reaction to replenish the intermediates of the tricarboxylic acid cycle. 3-Hydroxyvaleric acid is one of the important monomers for the synthesis of polyhydroxyalkanoates (PHA). PHA is a type of biodegradable plastic that is widely used in environmentally friendly packaging, disposable products, and medical materials.
    3-Hydroxyvaleric acid
  • HY-113080
    N-Acetylornithine 6205-08-9 ≥98.0%
    N-Acetylornithine is a precursor of ornithine. N-Acetylornithine is associated with type 2 diabetes.
    N-Acetylornithine
  • HY-126050
    (R)-Pantetheine 496-65-1 ≥99.0%
    (R)-Pantetheine is the biosynthetic precursor to CoA. (R)-Pantetheine and its corresponding disulfide pantethine, play a key role in metabolism as a building block of coenzyme A (CoA). (R)-Pantetheine has high toxicity.
    (R)-Pantetheine
  • HY-134426
    DL-β-Hydroxybutyryl coenzyme A lithium 103404-51-9 ≥98.0%
    DL-β-Hydroxybutyryl coenzyme A lithium is an intermediate in the fermentation of butyric acid and the metabolism of lysine and tryptophan, and is produced from β-hydroxybutyric acid by short-chain-CoA synthase.
    DL-β-Hydroxybutyryl coenzyme A lithium
  • HY-13771A
    Ursodeoxycholic acid sodium 2898-95-5 ≥98.0%
    Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active.
    Ursodeoxycholic acid sodium
  • HY-141700
    FATP1-IN-2 2650944-83-3 98.83%
    FATP1-IN-2 (compound 12a), an arylpiperazine derivative, is an orally active fatty acid transport protein 1 (FATP1) inhibitor (human IC50=0.43 μM, mouse IC50=0.39 μM).
    FATP1-IN-2
  • HY-153523
    Hi 76-0079 374567-94-9 99.90%
    Hi 76-0079 (Compound 31) is a hormone-sensitive lipase (HSL) inhibitor with an IC50 of 184 nM.
    Hi 76-0079
  • HY-P0054B
    GLP-1(7-36), amide TFA 98.66%
    GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
    GLP-1(7-36), amide TFA
  • HY-P0276A
    GIP, human TFA 99.88%
    GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.
    GIP, human TFA
  • HY-108801A
    Aflibercept (VEGF Trap) 862111-32-8
    Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.
    Aflibercept (VEGF Trap)
  • HY-113270A
    Actinine chloride 6249-56-5 ≥98.0%
    Actinine (γ-Butyrobetaine) chloride is angiopathic substance produced as an intermediary metabolite by gut microbiota that feed on carnitine in dietary red meat.
    Actinine chloride
  • HY-146248B
    TFMU-ADPr diammonium 98.02%
    TFMU-ADPr is a universal substrate for monitoring PARG activity. TFMU-ADPr directly reports the total bar number hydrolase activity by releasing fluorophore. TFMU-ADPr is a general tool for evaluating small molecule inhibitors and exploring the regulation of ADP-ribose catabolic enzymes in vitro.
    TFMU-ADPr diammonium
  • HY-W011012
    Adenosine 5'-monophosphate disodium 4578-31-8
    Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes.
    Adenosine 5'-monophosphate disodium
  • HY-W016409
    Ethyl 3,4-dihydroxybenzoate 3943-89-3 99.96%
    Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
    Ethyl 3,4-dihydroxybenzoate
  • HY-18282
    AZ876 898800-26-5 99.93%
    AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis.
    AZ876
  • HY-15790
    Elobixibat 439087-18-0 ≥98.0%
    Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
    Elobixibat
  • HY-16781
    Grapiprant 415903-37-6 99.57%
    Grapiprant (CJ-023423) is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2). Grapiprant displaces [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor with IC50 value of 35 nM and Ki value of 24 nM. Grapiprant has the potential for osteoarthritic pain and inflammation treatment[3] .
    Grapiprant
Cat. No. Product Name / Synonyms Application Reactivity